Stopping GLP-1 Medications: Weight Regain Data, Tapering, and What to Plan For

If you want the short answer first: most people regain a meaningful amount of weight after stopping a GLP-1 medication, and the rebound often starts sooner than they expect. In the STEP 1 extension, people who had lost 17.3% of body weight on semaglutide regained 11.6 percentage points over the following year after treatment stopped, which worked out to roughly two-thirds of the lost weight returning. ^[1] Newer meta-analyses tell the same story at a population level: regain often becomes measurable within 8 weeks, gets larger over longer follow-up, and is usually paired with worsening blood sugar, blood pressure, and waist circumference. ^{[4] [5]} A 2026 BMJ meta-analysis put the average regain after stopping semaglutide or tirzepatide at about 0.8 kg (1.8 lb) per month. ^[11] That does not mean stopping is a mistake. It means stopping should be planned.

If you need the broader medication background first, start with our complete GLP-1 medications guide. If cost is the reason you are considering stopping, keep our telehealth comparison and our guide to the cheapest ways to get a GLP-1 in 2026 open too, because access problems are one of the most common reasons treatment ends.

How much weight do people regain after stopping a GLP-1?

The cleanest semaglutide withdrawal data still come from the STEP 1 trial extension. Participants without diabetes took semaglutide 2.4 mg for 68 weeks, then stopped both the medication and the trial’s structured lifestyle support. Over the next year:

• average weight loss during treatment was 17.3%
• average regain after stopping was 11.6 percentage points
• net weight remained 5.6% below baseline at week 120
• 48.2% still kept off at least 5% of baseline weight one year later ^[1]

That is the number many readers need to hear plainly: the average person in that extension did not regain everything within a year, but they did regain most of what they had lost.

The randomized withdrawal trials show the same pattern. In STEP 4, adults first took semaglutide 2.4 mg for 20 weeks and lost an average of 10.6%. Over the next 48 weeks, weight rose 6.9% in people switched to placebo and fell another 7.9% in people who stayed on semaglutide, even though both groups kept getting lifestyle counseling. ^[2] Tirzepatide showed the same basic problem in SURMOUNT-4. After 36 weeks on the highest tolerated dose (10 or 15 mg), people had lost 20.9% on average. Over the following 52 weeks, weight rose 14.0% on placebo and fell another 5.5% on tirzepatide. By the end, 89.5% of people who stayed on tirzepatide had kept at least 80% of their earlier loss, compared with 16.6% on placebo. ^[3]

The newer meta-analyses help with the timeline question. A 2025 BMC Medicine review found that weight regain after anti-obesity medication discontinuation became significant by 8 weeks and remained significant through 20 weeks. ^[4] A 2025 eClinicalMedicine meta-analysis found that, among people with obesity, GLP-1 receptor agonist discontinuation was associated with pooled regain of 5.63 kg, with larger rebound in studies that followed people for more than 26 weeks. ^[5]

The largest recent pooled analysis, published in the BMJ in January 2026, combined 37 studies with 9,341 participants. For semaglutide and tirzepatide, people had lost an average of 14.7 kg on treatment. After stopping, they regained about 0.8 kg (1.8 lb) per month, or about 9.9 kg (22 lb) in the first year. The authors projected a return to starting weight about 1.5 years after stopping these two drugs. Treat that as an estimate: data for semaglutide and tirzepatide ran only 12 months after stopping, and the rest is a trend line. Across all weight-loss medicines in the review, weight came back faster than after behavioral weight-loss programs, even after accounting for how much weight people had lost. ^[11]

The withdrawal studies side by side

Study	Drug	Weight lost on the drug	What happened after stopping
STEP 1 extension	Semaglutide 2.4 mg	17.3% over 68 weeks	Regained 11.6 percentage points in 1 year, still 5.6% below starting weight [1]
STEP 4	Semaglutide 2.4 mg	10.6% over 20 weeks	Weight rose 6.9% over 48 weeks on placebo [2]
SURMOUNT-4	Tirzepatide 10 or 15 mg	20.9% over 36 weeks	Weight rose 14.0% over 52 weeks on placebo [3]
BMJ 2026 meta-analysis	Semaglutide or tirzepatide	14.7 kg on average	About 0.8 kg regained per month, about 9.9 kg in the first year [11]

A more honest way to frame the numbers

Readers often hear one of two bad summaries:

• “You gain it all back instantly.”
• “You can keep it off if you just stay disciplined.”

Neither is good enough.

The more accurate version is this: regain is common, often starts in the first few months, and usually continues over time if nothing else changes. But the amount varies. Some people keep off a clinically meaningful share of the original loss. Others regain faster, especially if they stopped because cost, side effects, or life stress had already disrupted eating, training, or follow-up.

The spread is wide. A 2026 analysis of SURMOUNT-4 followed 308 people who had lost at least 10% on tirzepatide and were then switched to placebo. After a year, 54 had regained less than a quarter of the weight they lost, and 74 had regained three-quarters or more. Most fell somewhere in between. ^[12]

What happens to blood sugar and blood pressure after stopping?

Stopping a GLP-1 changes more than appetite and the number on the scale.

In the STEP 1 extension, the cardiometabolic improvements seen during semaglutide treatment moved back toward baseline after withdrawal for most variables. ^[1] Blood pressure drifted back to baseline. HbA1c rose. C-reactive protein and lipids worsened from their week-68 lows, although some markers still looked modestly better than baseline after a year off treatment. ^[1]

The pooled evidence now supports the same direction of effect. In people with obesity, the eClinicalMedicine meta-analysis found that GLP-1 discontinuation was associated with:

• higher HbA1c
• higher systolic blood pressure
• larger waist circumference
• worsening LDL, triglycerides, and other lipid markers ^[5]

The worsening seems to track how much weight comes back. In the SURMOUNT-4 analysis, people who regained less than a quarter of their lost weight saw almost no change in waist size (+0.8 cm), while those who regained three-quarters or more added 14.7 cm. A1C rose 0.14 percentage points in the first group and 0.35 in the second. Systolic blood pressure rose in every group, by about 7 to 10 mm Hg, even among people who kept most of the weight off. ^[12] The BMJ review projected that blood sugar, blood pressure, and cholesterol return to starting levels within about 1.4 years after stopping a weight-loss medicine, though it had too little data to check this for semaglutide and tirzepatide alone. ^[11]

That matters for two reasons.

First, if you were using the medication mainly for obesity, the story is still bigger than aesthetics. Weight regain often brings back some of the metabolic risk you had improved while on treatment.

Second, if you were using a GLP-1 in the setting of diabetes or prediabetes, stopping deserves a tighter plan. In the STEP 1 extension, among participants who had prediabetes at baseline, 93.6% of semaglutide-treated participants were normoglycemic at week 68, but only 43.3% were normoglycemic a year after stopping. ^[1]

What about cardiovascular benefit?

This part needs careful wording. The strongest cardiovascular-outcomes evidence for semaglutide comes from ongoing treatment, not from people who stopped. In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes. ^[6]

What SELECT does not tell us is that the same protection persists after the drug is discontinued. So the honest takeaway is:

• semaglutide has proven cardiovascular benefit while patients are on it
• withdrawal studies show blood pressure and metabolic markers often worsen after stopping
• we do not have strong evidence that you keep the full cardiovascular benefit once treatment is gone ^{[1] [5] [6]}

Why does weight come back after stopping a GLP-1?

This is the section where the tone matters most. Regain after stopping a GLP-1 is not proof that you failed. It is exactly what weight-regulation biology would predict.

One part is medication-specific. Semaglutide reduces appetite, lowers ad libitum energy intake, and changes food preference in people with obesity. ^[8] If a medication has been making you less hungry and easier to satisfy, stopping it removes that effect.

The second part is broader human physiology. Weight loss itself triggers compensatory changes that favor regain: appetite rises, energy expenditure falls, and several appetite-related hormones move in the wrong direction for maintenance. That is why obesity researchers keep describing weight regain as a biological response rather than a simple motivation problem. ^[7]

That combination is what makes the post-GLP-1 phase hard:

• the drug’s appetite suppression fades
• the body is still defending against the lower weight
• daily habits that felt easy during treatment suddenly take more effort

That is also why shame is such a bad tool here. Shame does not change physiology. Planning does.

Is tapering better than stopping cold turkey?

Readers ask this constantly, and the evidence is not as settled as social media makes it sound.

Right now, we do not have a high-quality randomized trial proving the best tapering protocol for semaglutide or tirzepatide discontinuation. Anyone selling a single “correct” taper schedule is overpromising.

That gap is now being studied. A randomized trial in Canada called REST compares a gradual 16-week semaglutide dose reduction with stopping all at once, in about 98 participants. As of October 2026, ClinicalTrials.gov lists it as recruiting, with an estimated primary completion date of September 2028. ^[16]

What we do have is early observational evidence. At ECO 2024, investigators reported data from a digital multidisciplinary program of 2,246 participants using personalized semaglutide dosing. Among the 353 people who started tapering, the median taper phase lasted 9 weeks. Among patients who stopped semaglutide and were followed after cessation, average body weight was roughly stable at 26 weeks in the reported model, though about 1 in 5 had restarted semaglutide by 26 weeks and the program included continued support. ^[9]

That is interesting, but it is not the same as saying “tapering solves regain.” The limitations are obvious:

• it was not a randomized withdrawal trial
• participants were in an ongoing multidisciplinary program
• some restarted semaglutide
• most of the authors work for Embla, the company that runs the program
• as of October 2026, we could not find a full peer-reviewed paper with these results, only the conference abstract
• the results tell us more about a supported tapering pathway than a general rule for everyone ^[9]

What newer trials say about lower doses and switching

Two 2026 trials, both funded by Lilly, tested options between staying on full-dose treatment and stopping.

• A lower dose (SURMOUNT-MAINTAIN). 378 adults who had lost weight over 60 weeks on their highest tolerated tirzepatide dose (10 or 15 mg) were randomized to stay on that dose, step down to 5 mg, or switch to placebo for another 52 weeks. At week 112, weight was 21.9% below starting weight on the full dose, 16.6% on 5 mg, and 9.9% on placebo. People who regained more than half of their lost weight could get rescue tirzepatide from week 84. That happened for 8% of the full-dose group, 25% of the 5 mg group, and 67% of the placebo group. ^[13]
• Switching to a pill (ATTAIN-MAINTAIN). Adults who had taken tirzepatide or semaglutide injections in the SURMOUNT-5 trial were randomized to daily orforglipron (now sold as Foundayo) or placebo for 52 weeks. Among people whose weight had plateaued, those coming off tirzepatide kept 74.7% of their weight loss on orforglipron versus 49.2% on placebo. Those coming off semaglutide kept 79.3% versus 37.6%. The trial lasted one year and had no group that stayed on injections. ^[14] Our Foundayo guide covers the pill itself.

Neither trial tested a taper to zero. Both suggest that staying on some medication, at a lower dose or in a different form, holds more of the loss than stopping. Neither shows that the lower dose or the pill works as well as the full injectable dose, and in SURMOUNT-MAINTAIN the 5 mg dose kept off less weight than the full dose. ^{[13] [14]}

So the practical answer is:

1. Tapering may be reasonable, especially if you are trying to reduce side effects, step down gradually, or test whether a lower dose is enough.
2. Tapering is not DIY territory. The stopping plan should match why you are stopping: cost, pregnancy planning, GI side effects, diabetes control, cardiovascular disease, or simply having reached a goal.
3. A lower maintenance dose may be more realistic than complete discontinuation for some patients, but that is a prescriber conversation, not a universal rule. ^[13]

What gives you the best chance of keeping more of the loss

This is the part where honesty matters again. Guidelines recommend ongoing nutrition and lifestyle support for weight maintenance, and these steps help protect muscle and function. But no controlled trial has tested whether a structured nutrition or lifestyle program after stopping a GLP-1 prevents regain. ^[15] In the BMJ review, the rate of regain did not differ by the type of support people got after stopping, though few studies compared this directly. ^[11] These steps may help, but they do not erase rebound risk.

1. Keep resistance training in the plan

If you stop the medication and also stop training, you are stacking the deck against yourself. Resistance training helps preserve lean mass, supports function, and gives you at least some protection against the metabolic slowdown that follows weight loss. If you need help building that routine, use our GLP-1 exercise guide and our deeper piece on muscle loss on GLP-1.

2. Keep protein high enough to be deliberate

The maintenance phase is where protein often quietly falls apart. A 2025 joint advisory from four obesity and nutrition societies notes that targets of about 1.2 to 1.6 g/kg/day have been proposed during active weight loss, above the general adult RDA of 0.8 g/kg/day. Because it is unclear which body weight to use in people with obesity, the advisory also offers a simpler range of 80 to 120 g per day. ^[15] Higher protein intake is commonly used to support function and lean-mass preservation, especially in older adults. The PROT-AGE group recommends more protein for older adults with acute or chronic illness, but less for those with severe kidney disease who are not on dialysis. ^[10] Your clinician can help set a target that fits your kidneys and health history.

If you want help turning that into meals, use our GLP-1 meal plan and macro targets guide.

3. Keep the structure you built on treatment

The easiest maintenance mistake is assuming the hard part is over, then drifting back into:

• skipped breakfasts that turn into evening overeating
• less protein
• less sleep
• less planned movement
• more “I’ll get back on track Monday”

The people who keep more of the loss usually do not rely on motivation alone. They keep some version of a repeatable meal pattern, a protein floor, and a weekly reality check.

4. Watch the first 8 to 12 weeks closely

Because regain can start early, this is not the time to stop paying attention. A weekly weigh-in, waist measurement, symptom log, or glucose check may be enough to spot drift before it turns into a discouraging spiral.

5. Decide in advance what counts as a problem

Some people would be fine keeping off 5% of baseline weight and accepting partial regain. Others are stopping for diabetes, cardiovascular disease, or severe sleep apnea, where the clinical stakes are higher. Know your threshold before you stop:

• How much regain would make you reconsider treatment?
• What glucose or blood-pressure change would trigger a call?
• Is the goal complete discontinuation, or a lower-dose maintenance plan?

When staying on long term makes sense, and when stopping is reasonable

Obesity is now widely framed as a chronic, relapsing disease, which is one reason long-term treatment is not inherently a failure or a crutch. The withdrawal data fit that model pretty well. ^{[1] [5]}

Staying on long term often makes more sense when:

• you have repeatedly regained after prior stops
• you have type 2 diabetes, prediabetes, or high cardiometabolic risk
• food noise, appetite, or binge-prone eating return quickly off treatment
• the medication is still tolerable and affordable
• you have established cardiovascular disease and the on-treatment benefit matters ^{[5] [6]}

Stopping is also reasonable in real life when:

• cost or insurance makes long-term access unstable
• side effects remain too disruptive
• pregnancy planning or another medical issue changes the risk-benefit balance
• you reached a target and want to try a lower-intensity maintenance phase
• you and your prescriber agree that the next step is a monitored taper or stop rather than indefinite continuation

The bad version of this conversation is “either I stay on forever or I failed.” The better version is “if I stop, what is my maintenance plan, and what is my threshold for changing course?”

Questions to ask your prescriber before you stop

Take these to the visit:

1. What is the main reason I am stopping, and does that reason change how quickly you want me to taper?
2. What amount of regain would you consider expected versus concerning in my case?
3. If I have diabetes or prediabetes, how should we monitor glucose or A1c after I stop?
4. If the main issue is cost, is a lower-dose maintenance plan, coverage appeal, or alternative medication more realistic than full discontinuation?
5. What symptoms or lab changes would make you want me to restart, switch, or come back sooner?
6. What is my protein, exercise, and follow-up plan for the first 8 to 12 weeks off treatment?

That last question is the one people skip most often, and it is usually the one that matters most.

Bottom line

Stopping a GLP-1 is not morally wrong, and it is not medically trivial.

The evidence says most patients regain a meaningful amount of weight after stopping, often beginning within the first few months. Blood sugar, blood pressure, and other metabolic improvements often worsen too. But some people still keep off part of the loss, and a planned stopping phase gives you a way to catch regain early. ^{[1] [4] [5] [11]}

If you are considering stopping because of cost, side effects, or because you reached your goal, the most useful framing is not “Will I regain?” It is “How much risk am I willing to accept, and what is my plan if the rebound starts?”